RecruitingPHASE2, PHASE3NCT06193889
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Studying Adult-onset myasthenia gravis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Kyverna Therapeutics
- Principal Investigator
- MD, MDKyverna Therapeutics, Inc.
- Intervention
- Standard of Care Treatment(drug)
- Enrollment
- 66 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2024 – 2028
Study locations (14)
- University of California, Irvine, Orange, California, United States
- Stanford University Medical Center, Palo Alto, California, United States
- University of Miami, Miami, Florida, United States
- Indiana University Health, Indianapolis, Indiana, United States
- Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
- Houston Methodist Hospital, Houston, Texas, United States
- Intermountain Medical Center, Murray, Utah, United States
- Hospital Israelita Albert Einstein, São Paulo, Brazil
- Charite- Universitätsklinikum Berlin, Berlin, Germany
- Universitätsklinikum der Ruhr-Universität Bochum, Bochum, Germany
- Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
- Medizinische Hochscule Hannover, Hanover, Germany
- Friedrich-Schiller-Universität Jena, Jena, Germany
- Universitätsklinik Magdeburg, Magdeburg, Germany
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06193889 on ClinicalTrials.govOther trials for Adult-onset myasthenia gravis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06987539A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)Amgen
- RECRUITINGPHASE2NCT07501702A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia GravisVertex Pharmaceuticals Incorporated
- RECRUITINGPHASE1NCT07526493Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.Tongji Hospital
- RECRUITINGNANCT07413835Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)The Affiliated Hospital of Xuzhou Medical University
- RECRUITINGPHASE1, PHASE2NCT07089121Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune DisordersCartesian Therapeutics
- RECRUITINGPHASE1NCT07304154A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic DiseasesKite, A Gilead Company
- RECRUITINGPHASE4NCT07221838A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With RavulizumabAlexion Pharmaceuticals, Inc.
- RECRUITINGPHASE1, PHASE2NCT07250750A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia GravisImmunAbs Inc.